Chest
-
Late Breaking AbstractsSESSION TYPE: Slide PresentationPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMPURPOSE: Within 2 weeks in Nov 2013, there were 8 pediatric cases of complicated pneumonia admitted to 6 pediatric ICU in Hong Kong, resulting in 2 deaths associated with hemolytic uremic syndrome. This outbreak led to this description study of the changing epidemiology of complicated pneumonia and associated hemolytic uremic syndrome in children. ⋯ The following authors have nothing to disclose: Gary Wong, Ting Leung, Chante NgNo Product/Research Disclosure Information.
-
Cardiovascular Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Carfilzomib is a novel chemotherapy agent for the treatment of relapsed and refractory Multiple Myeloma (MM). It is a selective, irreversible proteasome inhibitor that induces apoptosis of myeloma cells. It was approved by US-FDA in July 2012. ⋯ The following authors have nothing to disclose: Sameer Chadha, Rahul Yadav, Kunal Teli, Guy Kulbak, Gerald Hollander, Jacob ShaniNo Product/Research Disclosure Information.
-
OSA & COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: OSAS is an independent risk factor for asthma exacerbations and OSAS symptoms are more common in asthmatic patients than in the general population. This study correlates number of exacerbations with AHI in 24 stable asthmatics with overlap of OSAMETHODS: 24 stable patients' of BA with overlap of OSA diagnosed on PSG, using or not using CPAP, attending outpatient clinic of Metro Centre for Respiratory diseases were retrospectively analysed for number of exacerbations in last one year using SPSS software. ⋯ The following authors have nothing to disclose: Mayuri Johari, Karn Mehra, Deepak TalwarNo Product/Research Disclosure Information.
-
Respiratory Infections PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Vancomycin is standard of care for the treatment of methicillin-resistant Staphylococcus aureus infection (MRSA). Conventional dosing strategies are intermittent dosing with assessment of therapeutic level. First trough level is obtained before the 4th dose. It often results in readjusting dose and frequency of vancomycin to obtain adequate levels. As the mortality rate for MRSA bacteremia remains high 23.4%, no study has looked at continuous infusion vancomycin (CIV) since the IDSA guidelines in 2009 changing therapeutic level interpretation. We conducted a retrospective review at our academic center to review steady state levels, complications and morbidity. ⋯ The following authors have nothing to disclose: Syed Masood, Christopher Droege, Renee Hebbeler-ClarkNo Product/Research Disclosure Information.
-
COPD Comorbidity PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: 1.To observe cardiovascular (both left as well as right heart function) effects in COPD patients. 2.To evaluate role of thorough cardiovascular check up as a routine in COPD patient including ECG and ECHO study to manage the COP syndrome. ⋯ The following authors have nothing to disclose: Deepak SinghNo Product/Research Disclosure Information.